Dcr-Phxc clinical trials
Dcr-Phxc is named as an intervention in 2 current clinical trials in our UK, USA, Germany, France, Spain, Italy, Netherlands, Norway, Turkey, Canada, Japan and Australia registers. 1 is recruiting patients now. The most common phase is Phase 2. The lead sponsor is Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. The most-studied condition is Primary Hyperoxaluria Type 1.
How Dcr-Phxc works
All drug targets →- L-lactate dehydrogenase A chain mRNA RNAi inhibitor Rnai inhibitorTarget: LDHA lactate dehydrogenase AChEMBL only
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4594338, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13615, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Dcr-Phxc
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Dcr-Phxc
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
NCT04580420 · Primary Hyperoxaluria Type 1, End Stage Renal Disease
|
Phase 2 | Recruiting | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | UK, USA, Germany, France, Spain, Italy |
|
Long Term Extension Study in Patients With Primary Hyperoxaluria
NCT04042402 · Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases
|
Phase 3 | Active, closed | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | UK, USA, Germany, France, Spain, Italy, Netherlands, Norway, Turkey, Canada, Japan, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Dcr-Phxc
6 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2 |
By country register
A trial with sites in more than one country appears in each of those registers.
Questions about Dcr-Phxc trials
How many clinical trials are testing Dcr-Phxc?
2 current trials in our UK, USA, Germany, France, Spain, Italy, Netherlands, Norway, Turkey, Canada, Japan and Australia registers name Dcr-Phxc as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Dcr-Phxc trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in UK, 1 with sites in USA, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain and 1 with sites in Italy. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Dcr-Phxc clinical trials?
The lead sponsor is Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Dcr-Phxc works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Dcr-Phxc works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Dcr-Phxc (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.